Dupixent is about to enter the last hurdle of expanding insurance reimbursement coverage for young children.

According to industry sources, the Ministry of Health and Welfare (MOHW) has recently ordered drug pricing negotiations for Sanofi Korea’s Dupixent (dupilumab). Consequently, a tug-of-war between the government and Sanofi is about to start.

Dupixent is covered by reimbursement for severe atomic dermatitis over the age of 6 years. If it completes the drug pricing negotiations and secures expanded reimbursement, prescriptions will become available to infants six months and above. This indication was approved in South Korea in November 2022.

There have been